FRI-009-Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with prolonged predicted survival even in patients with incomplete biochemical improvements

Authors :: Alexandra Rousseau
Christophe Corpechot
Olivier Chazouillères
Sara Lemoinne
Karima Ben Belkacem
Gaouar Farid
Raoul Poupon
Source :: Journal of Hepatology. 70:e386-e387
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Add on therapy
medicine.medical_specialty
Bezafibrate
Hepatology
business.industry
Internal medicine
medicine
In patient
business
Gastroenterology
medicine.drug

Full Text Access

Tools